William K. Hagmann

7.2k citations

78 papers · 5.4k indexed · 1 hit paper · h-index 25

Co-authors: Alice I. Marcy Jeffrey D. Hermes Malcolm MacCoss Craig K. Esser James P. Springer Ginger X. Yang Richard A. Mumford Thomas J. Lanza
Topics: Peptidase Inhibition and Analysis (25 papers)Cell Adhesion Molecules Research (18 papers)Protease and Inhibitor Mechanisms (14 papers)
Cited by: Pharmaceutical Science Organic Chemistry Inorganic Chemistry
Journals: Nature Journal of the American Chemical Society Journal of Biological Chemistry
Partner nations: United States

In The Last Decade

William K. Hagmann

78 papers receiving 5.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Many Roles for Fluorine in Medicinal Chemistry

2008 3.2k citations William K. Hagmann Journal of Medicinal Chemistry profile →

Peers

Countries citing papers authored by William K. Hagmann

Since Specialization

Citations

This map shows the geographic impact of William K. Hagmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William K. Hagmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William K. Hagmann more than expected).

Fields of papers citing papers by William K. Hagmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William K. Hagmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William K. Hagmann. The network helps show where William K. Hagmann may publish in the future.

Co-authorship network of co-authors of William K. Hagmann

This figure shows the co-authorship network connecting the top 25 collaborators of William K. Hagmann. A scholar is included among the top collaborators of William K. Hagmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William K. Hagmann. William K. Hagmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production 2017 ·PLoS ONE ·Corin O. Miller,(unknown),(unknown),(unknown),(unknown),(unknown),Jin Cao,(unknown),Brande Thomas-Fowlkes,Jerry Di Salvo,Adam B. Weinglass,Xiaoyan Li,Robert W. Myers,Kevin Knagge,Paul E. Carrington,William K. Hagmann,Maria E. Trujillo	10
2	Discovery of substituted (4-phenyl-1H-imidazol-2-yl)methanamine as potent somatostatin receptor 3 agonists 2015 ·Bioorganic & Medicinal Chemistry Letters ·Zhong Lai,Shuwen He,Edward C. Sherer,Zhicai Wu,(unknown),Richard Ball,Qingmei Hong,David Yang,(unknown),Derun Li,(unknown),Gary G. Chicchi,(unknown),Kwei‐Lan Tsao,Yunping Zhou,Andrew D. Howard,Ravi P. Nargund,William K. Hagmann	2
3	Synthesis and cannabinoid-1 receptor binding affinity of conformationally constrained analogs of taranabant 2010 ·Bioorganic & Medicinal Chemistry Letters ·Ihor E. Kopka,Linus S. Lin,James P. Jewell,Thomas J. Lanza,Tung M. Fong,Chun-Pyn Shen,(unknown),Sookhee Ha,(unknown),Lex Van der Ploeg,Mark T. Goulet,William K. Hagmann	6
4	Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists 2009 ·Bioorganic & Medicinal Chemistry Letters ·Wu Du,James P. Jewell,Linus S. Lin,Vincent J. Colandrea,Jing Chen Xiao,Julie Lao,Chun-Pyn Shen,Thomas J. Bateman,(unknown),Sookhee Ha,Shrenik K. Shah,Tung M. Fong,Jeffrey J. Hale,William K. Hagmann	7
5	Similar in vitro pharmacology of human cannabinoid CB1 receptor variants expressed in CHO cells 2008 ·Brain Research ·Jing Chen Xiao,James P. Jewell,Linus S. Lin,William K. Hagmann,Tung M. Fong,Chun-Pyn Shen	15
6	Constraining the amide bond in N-Sulfonylated dipeptide VLA-4 antagonists 2008 ·Bioorganic & Medicinal Chemistry Letters ·Linda Chang,Ginger X. Yang,Ermengilda McCauley,Richard A. Mumford,John A. Schmidt,William K. Hagmann	8
7	The Discovery of Taranabant, a Selective Cannabinoid‐1 Receptor Inverse Agonist for the Treatment of Obesity 2008 ·Archiv der Pharmazie ·William K. Hagmann	27
8	Synthesis of analogs of (1,4)-3- and 5-imino oxazepane, thiazepane, and diazepane as inhibitors of nitric oxide synthases 2004 ·Bioorganic & Medicinal Chemistry Letters ·K. Shankaran,(unknown),Shrenik K. Shah,Charles G. Caldwell,(unknown),William K. Hagmann,Malcolm MacCoss,John L. Humes,Stephen G Pacholok,Theresa M. Kelly,Stephan K. Grant,Kenny K. Wong	17
9	The Discovery and Potential of N-Sulfonylated Dipeptide VLA-4 Antagonists 2004 ·Current Topics in Medicinal Chemistry ·William K. Hagmann	11
10	Amidines as amide bond replacements in VLA-4 antagonists 2004 ·Bioorganic & Medicinal Chemistry Letters ·Theodore M. Kamenecka,(unknown),Linus S. Lin,(unknown),Ermengilda McCauley,Gail Van Riper,Linda A. Egger,(unknown),Richard A. Mumford,Sharon Tong,Wei Tang,Adria Colletti,Yohannes Teffera,Ralph A. Stearns,Malcolm MacCoss,John A. Schmidt,William K. Hagmann	15
11	Bioisosteric replacement of anilide with benzoxazole: potent and orally bioavailable antagonists of VLA-4 2004 ·Bioorganic & Medicinal Chemistry Letters ·Linus S. Lin,Thomas J. Lanza,Laurie A. Castonguay,Theodore M. Kamenecka,(unknown),Gail Van Riper,Linda A. Egger,Richard A. Mumford,Xinchun Tong,Malcolm MacCoss,John A. Schmidt,William K. Hagmann	14
12	A Small Molecule Very Late Antigen–4 Antagonist Can Inhibit Ovalbumin-induced Lung Inflammation 2003 ·American Journal of Respiratory and Critical Care Medicine ·Gloria C. Koo,Kashmira Shah,G J Ding,Jianying Xiao,Richard Wnek,George Doherty,Xin Tong,R. Blake Pepinsky,Ko‐Chung Lin,William K. Hagmann,D W Kawka,Irwin Singer	36
13	Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques 2003 ·Journal of Mass Spectrometry ·Koppara Samuel,(unknown),Ralph A. Stearns,Yui S. Tang,Ashok Chaudhary,James P. Jewell,Thomas J. Lanza,Linus S. Lin,William K. Hagmann,David C. Evans,Sanjeev Kumar	53
14	VLA‐4 antagonists: Potent inhibitors of lymphocyte migration 2003 ·Medicinal Research Reviews ·Ginger X. Yang,William K. Hagmann	64
15	N-Aryl 2,6-Dimethoxybiphenylalanine Analogues as VLA-4 Antagonists 2002 ·Bioorganic & Medicinal Chemistry Letters ·George Doherty,Theodore M. Kamenecka,(unknown),Gail Van Riper,Richard A. Mumford,Sharon Tong,William K. Hagmann	44
16	Potent, orally absorbed glucagon receptor antagonists 1999 ·Bioorganic & Medicinal Chemistry Letters ·Stephen E. de Laszlo,(unknown),Bing Li,Dooseop Kim,Malcolm MacCoss,Nathan B. Mantlo,James V. Pivnichny,(unknown),Gregory Koch,Margaret A. Cascieri,William K. Hagmann	150
17	Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor 1999 ·Journal of Biological Chemistry ·Margaret A. Cascieri,Gregory Koch,Elżbieta Ber,Sharon Sadowski,(unknown),Stephen E. de Laszlo,(unknown),William K. Hagmann,Malcolm MacCoss,Gary G. Chicchi,Pasquale P. Vicario	71
18	Use of an antibody against the matrix metalloproteinase–generated aggrecan neoepitope fvdipen‐cooh to assess the effects of stromelysin in a rabbit model of cartilage degradation 1995 ·Arthritis & Rheumatism ·E K Bayne,Karen L. MacNaul,Susan Donatelli,(unknown),Patrick R. Griffin,Lori A. Hoerrner,Jimmy Calaycay,Julia M. Ayala,Kevin T. Chapman,William K. Hagmann,Jeffrey R. Weidner,Joseph McDonnell,Vernon L. Moore,Richard A. Mumford,Michael W. Lark,Nancy I. Hutchinson	15
19	Secondary structure and zinc ligation of human recombinant short-form stromelysin by multidimensional heteronuclear NMR 1993 ·Biochemistry ·Paul R. Gooley,Bruce A. Johnson,Alice I. Marcy,(unknown),Scott P. Salowe,William K. Hagmann,Craig K. Esser,James P. Springer	43
20	Substituted 4,6-diaminoquinolines as inhibitors of C5a receptor binding 1992 ·Journal of Medicinal Chemistry ·Thomas J. Lanza,Philippe L. Durette,Thomas E. Rollins,Salvatore Siciliano,(unknown),Sumire Kobayashi,Charles G. Caldwell,Martin S. Springer,William K. Hagmann	72

About William K. Hagmann

William K. Hagmann is a scholar working on Immunology and Allergy, Cancer Research and Oncology, having authored 78 papers that have together received 5.4k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (25 papers), Cell Adhesion Molecules Research (18 papers) and Protease and Inhibitor Mechanisms (14 papers). The work is most often cited by research in Pharmaceutical Science (2.5k citations), Organic Chemistry (3.2k citations) and Inorganic Chemistry (864 citations). William K. Hagmann has collaborated with scholars based in United States. Frequent co-authors include Alice I. Marcy, Jeffrey D. Hermes, Malcolm MacCoss, Craig K. Esser, James P. Springer, Ginger X. Yang, Richard A. Mumford, Thomas J. Lanza, Arthur G. Schultz and Linus S. Lin. Their work appears in journals such as Nature, Journal of the American Chemical Society and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact